Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00019929
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
NIH
Sponsor class
Conditions
Lung Cancer
Interventions
BIOLOGICAL:
mutant p53 peptide pulsed dendritic cell vaccine
PROCEDURE:
adjuvant therapy
Sponsor
National Cancer Institute (NCI)